Aspirin therapy and primary prevention of cardiovascular disease in diabetes mellitus

Diabetes, Obesity and Metabolism

Volumn 11, Issue 11, 2009, Pages 997-1000

  Younis, Naveed ^a   Williams, Steve ^a   Soran, Handrean ^b  

^a MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^b MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

Aspirin; Cardiovascular diseases; Clinical guidelines; Diabetes mellitus

Indexed keywords

ACETYLSALICYLIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETES MELLITUS; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HEART PROTECTION; HUMAN; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; PATIENT COMPLIANCE; PRIMARY PREVENTION; REVIEW; RISK REDUCTION; STROKE; THERAPY RESISTANCE;

ASPIRIN; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; DIABETIC ANGIOPATHIES; FEMALE; FIBRINOLYTIC AGENTS; GREAT BRITAIN; HUMANS; MALE; MIDDLE AGED; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 70350166984     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2009.01068.x     Document Type: Review

References (19)

1. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008, 358:580-591.
2. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998, 339:229-234.
3. Barnett AH. Treating to goal: challenges of current management. Eur J Endocrinol 2004, 151(Suppl. 2):T3-T7.
4. Ferroni P, Basili S, Falco A, Davi G. Platelet activation in type 2 diabetes mellitus. J Thromb Haemost 2004, 2:1282-1291.
5. Natarajan A, Zaman AG, Marshall SM. Platelet hyperactivity in type 2 diabetes: role of antiplatelet agents. Diab Vasc Dis Res 2008, 5:138-144.
6. Antithrombotic Trialists' Collaborative Group. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death myocardial infarction and stroke in high risk patients. Br Med J 2002, 324:71-86.
7. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994, 308:81-106.
8. British Cardiac Society, British Hypertension Society, Diabetes UK, Heart UK, Primary Care Cardiovascular Society, The Stroke Association. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005, 91(Suppl. 5):v1-52.
9. American Diabetes Association. Standards of medical care in diabetes - 2009. Diabetes Care 2009, 32(Suppl. 1):S13-S61.
10. Clinical Guidance CG66. Diabetes Type 2 (update) 2008, Royal College of Physicians, London, UK
11. Belch J, MacCuish A, Campbell I. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. Br Med J 2008, 337:a1840.
12. Ogawa H, Nakayama M, Morimoto T. Low dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA 2008, 300:2134-2141.
13. Colwell JA, Nesto RW. The platelet in diabetes: focus on prevention of ischemic events. Diabetes Care 2003, 26:2181-2188.
14. Patrono C, Bachmann F, Baigent C. Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology. Eur Heart J 2004, 25:166-181.
15. Laine L. Review article: gastrointestinal bleeding with low-dose aspirin - what's the risk?. Aliment Pharmacol Ther 2006, 24:897-908.
16. Shantsila E, Lip GY. 'Aspirin resistance' or treatment non-compliance: this is to blame for cardiovascular complications?. J Transl Med 2008, 6:47.
17. Ajjan R, Storey RF, Grant PJ. Aspirin resistance and diabetes mellitus. Diabetologia 2008, 51:385-90.
18. Early Treatment Diabetic Retinopathy Study Group. Aspirin effects on mortality, morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. ETDRS Investigators. JAMA 1992, 268:1292-1300.
19. A study of cardiovascular events in diabetes. 2008, http://www.ctsu.ox.ac.uk/ascend/, Available from URL, Accessed 10 January 2009